Israeli AI Founder Maor Shlomo Launches Private Cancer Research Investment Fund
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
First reported by Calcalist · 15 hours ago
What happened
Maor Shlomo, founder of Israeli AI startup Base44, has launched a private investment fund focused on cancer research and innovative therapies, motivated by his mother's recent death from cancer. The fund has invested in seven companies over four months, aiming to accelerate drug development and testing through AI technologies. Shlomo calls for additional investors to join and plans to share further details soon.
- 01Maor Shlomo founded a private cancer research investment fund after losing his mother to cancer.
- 02The fund has invested in seven companies in four months, focusing on breakthrough therapies.
- 03Shlomo emphasizes AI's role in speeding drug design and identifies manufacturing and testing as new bottlenecks.
- 04He highlights companies like Starget Pharma, CuResponse, Cellint, and Baccine in his portfolio.
- 05Shlomo continues leading Base44 while supporting portfolio firms with AI expertise.
- 06He invites others to invest or assist and will announce more fund details later.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
